Yehuda Handelsman Selected Research

Insulin (Novolin)

2/2020	Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
12/2019	Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
2/2019	EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
1/2019	Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study.
1/2019	Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
12/2018	Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
9/2018	Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
3/2018	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS.
7/2017	Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
8/2016	CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yehuda Handelsman Research Topics

Disease

46	Type 2 Diabetes Mellitus (MODY) 12/2023 - 05/2007
17	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 03/2007
13	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 01/2017
8	Prediabetic State (Prediabetes) 01/2023 - 05/2009
6	Hypercholesterolemia 08/2022 - 02/2010
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2023 - 01/2017
5	Weight Loss (Weight Reduction) 12/2018 - 09/2015
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/2018 - 06/2016
4	Hypertension (High Blood Pressure) 01/2023 - 05/2010
4	Chronic Renal Insufficiency 01/2023 - 04/2017
4	Heart Failure 01/2023 - 01/2017
4	Myocardial Infarction 08/2022 - 01/2017
4	Stroke (Strokes) 08/2022 - 04/2017
4	Diabetes Mellitus 01/2020 - 01/2017
4	Atherosclerosis 04/2018 - 01/2017
3	Dyslipidemias (Dyslipidemia) 11/2023 - 01/2020
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 04/2017
3	Weight Gain 01/2019 - 09/2015
3	Nausea 09/2018 - 10/2014
2	Obesity 01/2023 - 04/2016
2	Atrial Fibrillation 01/2023 - 01/2022
2	Non-alcoholic Fatty Liver Disease 01/2023 - 01/2022
2	Kidney Diseases (Kidney Disease) 10/2019 - 04/2018
2	Vomiting 09/2018 - 10/2014
2	Diabetes Complications 09/2018 - 09/2009
2	Diarrhea 09/2018 - 10/2014
2	Body Weight (Weight, Body) 09/2018 - 04/2014
2	Hyperglycemia 09/2018 - 09/2015
2	Vascular Diseases (Vascular Disease) 07/2017 - 05/2017
2	Acute Coronary Syndrome 04/2017 - 04/2017
2	Homozygous Familial Hypercholesterolemia 04/2017 - 04/2017
2	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 04/2017 - 04/2017
2	Insulin Resistance 04/2017 - 01/2013
2	Thrombosis (Thrombus) 04/2017 - 01/2017
2	Infarction (Infarctions) 04/2017 - 01/2017
2	Hyperlipidemias (Hyperlipidemia) 07/2012 - 11/2009
1	Atrial Flutter (Flutter, Atrial) 01/2022
1	Cognitive Dysfunction 01/2022
1	Fournier Gangrene 01/2019
1	Chronic Disease (Chronic Diseases) 11/2018

Drug/Important Bio-Agent (IBA)

25	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 03/2007
16	Insulin (Novolin)FDA Link 02/2020 - 03/2007
13	LipidsIBA 01/2022 - 05/2009
12	LDL CholesterolIBA 01/2020 - 05/2009
10	Hemoglobins (Hemoglobin)IBA 01/2021 - 09/2009
10	Insulin Glargine (Lantus)FDA Link 02/2020 - 09/2009
10	oxidized low density lipoproteinIBA 01/2020 - 11/2009
10	Colesevelam Hydrochloride (Welchol)FDA Link 07/2012 - 05/2009
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2022 - 01/2012
7	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 12/2012
7	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 01/2010
7	Triglycerides (Triacylglycerol)IBA 07/2017 - 07/2010
6	Glucagon-Like Peptide-1 Receptor AgonistsIBA 11/2023 - 09/2018
6	insulin degludecIBA 02/2019 - 12/2012
6	Bile Acids and Salts (Bile Acids)IBA 05/2011 - 05/2009
5	CholesterolIBA 01/2020 - 04/2017
5	Blood Glucose (Blood Sugar)IBA 03/2018 - 05/2010
4	Sodium-Glucose Transport ProteinsIBA 11/2023 - 09/2015
4	lixisenatideIBA 02/2020 - 12/2018
4	Glucagon-Like Peptide-1 ReceptorIBA 02/2019 - 10/2014
4	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2018 - 12/2015
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 03/2018 - 04/2014
3	SodiumIBA 01/2020 - 06/2016
3	dapagliflozinIBA 01/2020 - 01/2019
3	Sitagliptin Phosphate (Januvia)FDA Link 01/2019 - 01/2010
3	omega-Chloroacetophenone (Mace)IBA 09/2018 - 04/2017
3	ApolipoproteinsIBA 04/2017 - 01/2017
3	Proprotein Convertase 9IBA 04/2017 - 01/2017
3	HDL CholesterolIBA 04/2017 - 01/2017
2	Eicosapentaenoic AcidIBA 08/2022 - 01/2017
2	PCSK9 InhibitorsIBA 01/2020 - 01/2018
2	Liraglutide FDA Link 02/2019 - 02/2017
2	IDegLiraIBA 02/2019 - 02/2017
2	evolocumabIBA 01/2019 - 12/2017
2	semaglutideIBA 09/2018 - 09/2018
2	C-Reactive ProteinIBA 04/2017 - 04/2017
2	Adenosine Triphosphate (ATP)IBA 04/2017 - 04/2017
2	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 04/2017 - 04/2017
2	VLDL CholesterolIBA 04/2017 - 04/2017
2	Fenofibrate (CiL)FDA LinkGeneric 04/2017 - 01/2017
2	BezafibrateIBA 04/2017 - 01/2017
2	Sodium-Glucose Transporter 2 InhibitorsIBA 06/2016 - 09/2015
2	Lipoproteins (Lipoprotein)IBA 01/2012 - 01/2010
2	Hormones (Hormone)IBA 09/2010 - 06/2008
1	Mineralocorticoid Receptor AntagonistsIBA 11/2023
1	EstersIBA 08/2022
1	eicosapentaenoic acid ethyl esterIBA 08/2022
1	Dronedarone FDA Link 01/2022
1	empagliflozinIBA 10/2019
1	CanagliflozinIBA 10/2019
1	saxagliptin FDA Link 01/2019
1	dulaglutideIBA 09/2018
1	Exenatide (Byetta)FDA Link 09/2018
1	Blood Proteins (Serum Proteins)IBA 04/2018
1	Glycated Serum ProteinsIBA 04/2018

Therapy/Procedure

23	Therapeutics 11/2023 - 03/2007
20	Glycemic Control 11/2023 - 05/2007
2	Secondary Prevention 01/2023 - 01/2020
2	Injections 03/2018 - 08/2016
1	Drug Therapy (Chemotherapy) 11/2023